• Quantitative Immunofluorescence was used to examine TumorInfiltrating Lymphocytes (TIL) in pretreatment NSCLC tumor samples.
• TIL levels of CD3, Granzyme B and Ki67 revealed a dormant phenotype of TIL’s in pretreatment tumor samples that correlated with clinical response to Checkpoint Inhibitor therapy.
• Patients with tumors displaying a combination of high CD3, low Granzyme B and low Ki67 levels displayed the best response to Checkpoint Therapy.
• Early evaluation of NSCLC tumors with this method may select patients most likely to benefit from these therapies.
• A PCT patent application has been filed.

Kaplan-Meier graphical analysis of 3-year progression free survival and overall survival of lung cancer cases treated with immune checkpoint blockers according to their TIL phenotype panel:

• Type 1: Low CD3
• Type 2: High CD3 + Low Granzyme B + Low Ki67
• Type 3: High CD3 + High Granzyme B OR High Ki67

The number of cases in each group and the log-rank P value is indicated in the chart.